NeOnc Technologies Completes Enrollment in Pivotal NEO100 Phase2a Trial for IDH-1 mutant Recurrent High‑Grade Glioma and Expects Interim Data Readout in SixMonths (Q22026)

Core Insights - NeOnc Technologies Holdings, Inc. has completed full patient enrollment in its NEO100-1 Phase 2a clinical trial, focusing on recurrent IDH1-mutant high-grade glioma [1][2] - Preliminary data from this fully enrolled cohort is expected to be reported in approximately six months, during the second quarter of 2026 [1] - The company emphasizes the potential of its intranasal therapy, NEO100, to achieve radiographic remission and durable survival in challenging CNS cancers [2] Company Overview - NeOnc Technologies is a clinical-stage life sciences company dedicated to developing CNS therapeutics that address the blood-brain barrier challenges [3] - The company's NEO drug development platform has produced novel drug candidates with patent protections extending to 2038 [3] - NEO100 and NEO212 are currently in Phase II human clinical trials and are advancing under FDA Fast-Track and IND status [3]